We are live on ! Find out more
PCM

Prelude Capital Management Portfolio holdings

AUM $1.31B
1-Year Est. Return 62.02%
This Fund
S&P 500
This Quarter Est. Return
+16.88%
1 Year Est. Return
+62.02%
3 Year Est. Return
+164.16%
5 Year Est. Return
+274.13%
10 Year Est. Return
+2,470.2%
AUM
$1.03B
AUM Growth
-$287M
Cap. Flow
-$398M
Cap. Flow %
-38.68%
Top 10 Hldgs %
14.04%
Holding
1,478
New
335
Increased
269
Reduced
346
Closed
503

Sector Composition

Rank Sector Weight
1 Technology 18.86%
2 Consumer Discretionary 12.74%
3 Healthcare 12.34%
4 Communication Services 10.34%
5 Industrials 8.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
BYD icon
201
Boyd Gaming
BYD
$6.06B
$1.29M 0.13%
16,468
+2,511
+18% +$179K
REG icon
202
Regency Centers
REG
$14.1B
$1.29M 0.13%
18,067
-8,164
-31% -$583K
ESSA
203
DELISTED
ESSA Bancorp
ESSA
$1.28M 0.12%
66,202
+50,443
+320% +$932K
ORCL icon
204
Oracle
ORCL
$423B
$1.28M 0.12%
5,839
-41,758
-88% -$6.74M
COMP icon
205
Compass
COMP
$9.66B
$1.27M 0.12%
202,675
-125,181
-38% -$857K
CART icon
206
Maplebear
CART
$11.8B
$1.27M 0.12%
28,107
-9,195
-25% -$400K
RSI icon
207
Rush Street Interactive
RSI
$2.88B
$1.27M 0.12%
85,273
+48,802
+134% +$606K
CFLT
208
DELISTED
Confluent
CFLT
$1.25M 0.12%
50,234
+37,195
+285% +$838K
MAG
209
DELISTED
MAG Silver
MAG
$1.25M 0.12%
59,199
+2,337
+4% +$41.5K
PAAS icon
210
Pan American Silver
PAAS
$21.6B
$1.25M 0.12%
43,951
+2,923
+7% +$75.6K
XBI icon
211
State Street SPDR S&P Biotech ETF
XBI
$10.3B
$1.24M 0.12%
15,000
+986
+7% +$78.7K
PI icon
212
Impinj
PI
$5.6B
$1.24M 0.12%
11,158
+1,772
+19% +$176K
BABA icon
213
Alibaba
BABA
$308B
$1.22M 0.12%
10,795
-6,660
-38% -$789K
EAT icon
214
Brinker International
EAT
$9.66B
$1.22M 0.12%
6,770
+511
+8% +$80.2K
LXP icon
215
LXP Industrial Trust
LXP
$3.57B
$1.22M 0.12%
+29,480
New +$1.21M
SMCI icon
216
Super Micro Computer
SMCI
$20.1B
$1.21M 0.12%
24,593
+4,333
+21% +$167K
LRCX icon
217
Lam Research
LRCX
$390B
$1.2M 0.12%
12,347
+4,391
+55% +$348K
WING icon
218
Wingstop
WING
$3.18B
$1.2M 0.12%
3,567
-937
-21% -$277K
MATW icon
219
Matthews International
MATW
$739M
$1.2M 0.12%
+50,182
New +$1.06M
AMD icon
220
Advanced Micro Devices
AMD
$789B
$1.19M 0.12%
8,418
+3,276
+64% +$357K
CCRN
221
DELISTED
Cross Country Healthcare
CCRN
$1.19M 0.12%
91,504
-57,871
-39% -$795K
GEN icon
222
Gen Digital
GEN
$17.5B
$1.19M 0.12%
+40,613
New +$1.11M
EQH icon
223
Equitable Holdings
EQH
$14.1B
$1.19M 0.12%
21,230
-3,406
-14% -$175K
TTD icon
224
Trade Desk
TTD
$6.49B
$1.18M 0.11%
16,400
+9,379
+134% +$599K
CYTK icon
225
Cytokinetics
CYTK
$10.4B
$1.17M 0.11%
35,501
+6,947
+24% +$242K

Similar funds

Prelude Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Prelude Capital Management held 1,478 positions worth $1.03B, down 22% from $1.32B the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Prelude Capital Management withdrew a net $398M in Q2 2025, closing 503 positions and reducing 346 holdings. Its most notable exit was Intra-Cellular Therapies Inc., an estimated $10.4M position sold in full.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 13% a quarter earlier, followed by Consumer Discretionary and Healthcare.

Against the trend, Prelude Capital Management opened a new position in Alphabet (Google) Class C worth $11.7M.

  • Prelude Capital Management's largest Q2 2025 buy was Alphabet (Google) Class C: 65,723 shares worth $11.7M.
  • Prelude Capital Management added most to Meta Platforms (Facebook) in Q2 2025, an estimated $12.3M increase.
  • Prelude Capital Management's biggest Q2 2025 reduction was Broadcom, cutting an estimated $9.33M.
  • Prelude Capital Management fully exited Intra-Cellular Therapies Inc. in Q2 2025, selling an estimated $10.4M.
  • Prelude Capital Management's ten largest holdings make up 14% of its $1.03B portfolio in Q2 2025.
  • Prelude Capital Management opened 335 new positions and closed 503 in Q2 2025.
  • Prelude Capital Management's portfolio value fell 22% quarter-over-quarter to $1.03B.

Based on Prelude Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.